摘要
目的探讨金水宝胶囊在噻托溴铵吸入剂治疗慢性阻塞性肺疾病中的作用。方法选取2015年9月至2018年9月牡丹江市中医医院呼吸科确诊慢性阻塞性肺疾病病例90例,随机分为两组。对照组规律吸入噻托溴铵粉吸入剂联合口服安慰剂,治疗组在规律吸入噻托溴铵基础上联合口服金水宝胶囊,用药1年。比较两组患者肺功能、临床疗效、慢性阻塞性肺疾病评估测试(CAT)评分、1年内上呼吸道感染发作次数。结果治疗后治疗组FEV_(1)/FVC、FEV_(1)、FVC均优于对照组,差异有统计学意义(P<0.05);治疗组中好转率及总有效率均高于对照组,差异有统计学意义(P<0.05),而其中显效率治疗组明显高于对照组,差异有统计学意义(P<0.01)。治疗组6个月及12个月CAT评分较对照组显著改善,差异有统计学意义(P<0.01)。一年内患者上呼吸道感染频次治疗组明显减少,与对照组比较,差异有统计学意义(P<0.01)。结论在噻托溴铵吸入剂治疗COPD中加入金水宝胶囊,能更加明显改善患者临床症状和肺功能,提高患者生活质量,显著减少上呼吸道感染次数。
Objective To explore the role of Jinshuibao capsule in the tr eatment of chronic obstructive pulmonary disease(COPD)with tiotropium bromide inhalation.Methods A total of 90 COPD cases diagnosed in the Respiratory Department of Mudanjiang Hospital of Traditional Chinese Medicine from September 2015 to September 2018 were selected.They were randomly divided into two groups.Patients with regular inhalation of tiotropium bromide powder combined with oral placebo were set as the control group,and the treatment group was combined with oral Jinshuibao capsule on the basis of regular inhalation of tiotropium bromide for one year.The pulmonary function,clinical efficacy,COPD assessment test(CAT)score and the incidence of upper respiratory tract infection in one year were compared between the two groups.Results After treatment,FEV_(1)/FVC,FEV_(1)and FVC in the treatment group were better than those in the control group,with statistically significant differences(P<0.05).The treatment improvement rate and total effective rate in the treatment group were significantly higher than those in the control group,with statistically significant differences(P<0.05),while the significant effective rate in the treatment group was significantly higher than that in the control group,with statistically significant difference(P<0.01).Compared with the control group,the CAT scores of the treatment group at 6 months and 12 months were significantly improved(P<0.01).In one year,the number of upper respiratory tract infections in the treatment group decreased significantly,which was significantly different from that in the control group(P<0.01).Conclusion The addition of Jinshuibao capsule to tiotropium bromide inhalation in the treatment of COPD can significantly improve the clinical symptoms and pulmonary function of patients,improve their quality of life and significantly reduce the number of upper respiratory tract infections.
作者
吕玉凤
姜爱英
卢统庆
高峰
韩磊
张丽
LV Yufeng;JIANG Aiying;LU Tongqing;GAO Feng;HAN Lei;ZHANG Li(Department of Respiratory and Critical Care,Hongqi Hospital Affiliated to Mudanjiang Medical University,Mudanjiang 157011,China;Department of Anesthesiology,Mudanjiang Hospital of Traditional Chinese Medicine in Heilongjiang Province,Mudanjiang 157011,China)
出处
《中国现代医生》
2022年第6期111-114,共4页
China Modern Doctor
基金
黑龙江省省属高等学校基本科研业务费科研项目(2018-KYYWF-0186)。
关键词
慢性阻塞性肺疾病
噻托溴铵粉吸入剂
金水宝胶囊
肺功能
Chronic obstructive pulmonary disease
Tiotropium bromide powder inhalation
Jinshuibao Capsule
Pulmonary function
